Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder

Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder - A Study to Evaluate the Effectiveness of an Intensive Treatment Week: "A Future Without Constraint"

Obsessive-compulsive disorders are very damaging illnesses; they can already appear in childhood and adolescence and become extremely chronic. With an average prevalence from 1-3%, they are among the most common psychiatric disorders in children and adolescents. 40% of diagnosed children and young adults display persistent and increasingly chronic symptoms and O-C disorders are highly complex syndromes with broadly varying manifestations. They arise from obsessive thoughts (ideas/thoughts or impulses, often senseless or tortured, that impose themselves or intrude) and obsessive behavior (ritualized patterns that must be frequently repeated).

Study Overview

• Status: Recruiting
• Conditions: Obsessive-Compulsive Disorder
• Intervention / Treatment: Behavioral: Short and Intensive Treatment

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Susanne Walitza, Prof. Dr. med. Dipl.-Psych.; Phone Number: +41 (0)43 499 26 26; Email: susanne.walitza@puk.zh.ch

Study Locations

• Switzerland
  • ZH
    • Zurich, ZH, Switzerland, 8032
      • Recruiting
      • Psychiatric University Clinics, Department of Child and Adolescent Psychiatry
      • Contact: Susanne Walitza, Prof. Dr. med. Dipl.-Psych.; Phone Number: +41 43 499 26 26; Email: susanne.walitza@puk.zh.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Obsessive-Compulsive Disorder diagnosis
• Male and female patients from 8-18 years
• Good German language speaking skills
• IQ of at least 75
• At least four days' participation in the treatment/therapy week
• Written agreement after clear explanation

Exclusion Criteria:

- No complete participation in the intensive week treatment/therapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Group; Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week.	Behavioral: Short and Intensive Treatment; Intensive Treatment Week with behavioural psychotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptoms severity of obsessive and compulsive symptoms in children and adolescents	The clinician-report questionnaire (BY-BOCS) contains 19 items designed to assess severity of obsessive and compulsive symptoms in children and adolescents.The test uses a 4-point scale to rate the severity of their obsessive compulsive behaviors. Higher score means a worse outcome.	12 months

Collaborators and Investigators

• Sponsor: Susanne Walitza
• Investigators: Principal Investigator: Susanne Walitza, Prof. Dr. med. Dipl.-Psych., Sponsor GmbH

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: January 25, 2021
• First Submitted That Met QC Criteria: January 25, 2021
• First Posted (Actual): January 29, 2021

Study Record Updates

• Last Update Posted (Actual): May 13, 2025
• Last Update Submitted That Met QC Criteria: May 12, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Personality Disorders; Anxiety Disorders; Compulsive Personality Disorder; Obsessive-Compulsive Disorder
• Other Study ID Numbers: KJPP 2020-02053

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No